Table 2.
UNC13D Inversion in Individuals With Lymphoma and Matched Controls
| Lymphoma | Controls | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Inv/wt | wt/wt | Carrier Frequency, % | Inv/wt | wt/wt | Carrier Frequency, % | OR | 95% CI | P | |
| All | 15 | 472 | 3.1 | 18 | 1826 | 1.0 | 3.0 | 1.5‐6.0 | .002 |
| Females | 10 | 226 | 4.2 | 10 | 893 | 1.1 | 3.7 | 1.5‐8.9 | .004 |
| Males | 5 | 246 | 2.0 | 8 | 933 | 0.9 | 2.2 | 0.7‐6.8 | .17 |
| NHL | 15 | 408 | 3.5 | 16 | 1578 | 1.0 | 3.4 | 1.7‐7.0 | .0006 |
| HL | 0 | 49 | 0.0 | 2 | 189 | 1.0 | 0.0 | 0‐inf | 1.0 |
Abbreviations: 95% CI, 95% confidence interval; HL, Hodgkin lymphoma; inf, infinity; Inv/wt, heterozygous carrier of UNC13D inversion; NHL, non‐Hodgkin lymphoma; OR, odds ratio; UNC13D, Unc‐13 homolog D; wt/wt, no UNC13D inversions.